Menatetrenon

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Menatetrenon
(IUPAC) ime
2-metil-3-[(2Z,6E,10E)-3,7,11,15-tetrametilheksadeka-2,6,10,14-tetraen-1-il]naftohinon
Klinički podaci
AHFS/Drugs.com Internacionalno ime leka
Identifikatori
CAS broj 863-61-6
ATC kod nije dodeljen
PubChem[1][2] 5282367
UNII 27Y876D139 DaY
KEGG[3] D00100 DaY
Hemijski podaci
Formula C31H40O2 
Mol. masa 444,648 g/mol
SMILES eMolekuli & PubHem
Sinonimi 3-metil-2-[(2Z,6E,10E)-3,7,11,15-tetrametilheksadeka-2,6,10,14-tetraenil]naftalen-1,4-dion
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Oralno

Menatetrenon (MK4) je menahinonsko jedinjenje koji se koristi kao hemostatički agens i kao dopunska terapija za bol uzrokovan osteoporozom. On je u prodaji za tu tretman osteoporoze u Japanu pod imenom Glakaj.

Menatetrenon jedna od devet formi vitamina K2.[4]

MK4 se formira konverzijom vitamina K1 u telu, testisima, pankreasu i arterijskim zidovima.[5] Mada biohemijski put transformacije vitamina K1 u MK4 nije potpuno razjašnjen, studije sugerišu da konverzija nije zavisna od bakterija u crevima.[6][7][8][9] Tkiva koja akumuliraju velike količine MK4 imaju veliki kapacitet konvertovanja dostupnog K1 u MK4.[10][11]

Reference[uredi | uredi kod]

  1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  4. ↑ Iwamoto J, Takeda T, Sato Y (December 2006). „Menatetrenone (vitamin K2) and bone quality in the treatment of postmenopausal osteoporosis”. Nutr. Rev. 64 (12): 509–17. DOI:10.1111/j.1753-4887.2006.tb00184.x. PMID 17274493. [mrtav link]
  5. ↑ Shearer, Shearer MJ; Newman P. (2008). „Metabolism and cell biology of vitamin K”. Thrombosis and Haemostasis: 530–547. DOI:10.1160/TH08-03-0147. 
  6. ↑ Davidson, RT; Foley AL, Engelke JA, Suttie JW (1998). „Conversion of Dietary Phylloquinone to Tissue Menaquinone-4 in Rats is Not Dependent on Gut Bacteria1”. Journal of Nutrition 128 (2): 220–223. PMID 9446847. 
  7. ↑ Ronden, JE; Drittij-Reijnders M-J, Vermeer C, Thijssen HHW. (1998). „Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat”. Biochimica et Biophysica Acta (BBA) - General Subjects 1379 (1): 69–75. DOI:10.1016/S0304-4165(97)00089-5. PMID 9468334. 
  8. ↑ Thijssen, HHW; Drittij-Reijnders MJ (1994). „Vitamin K distribution in rat tissues: dietary phylloquinone is a source of tissue menaquinone-4”. British Journal of Nutrition 72 (3): 415–425. DOI:10.1079/BJN19940043. PMID 7947656. 
  9. ↑ Will, BH; Usui Y, Suttie JW (1992). „Comparative Metabolism and Requirement of Vitamin K in Chicks and Rats”. Journal of Nutrition 122 (12): 2354–2360. PMID 1453219. 
  10. ↑ Davidson, RT; Foley AL, Engelke JA, Suttie JW (1998). „Conversion of Dietary Phylloquinone to Tissue Menaquinone-4 in Rats is Not Dependent on Gut Bacteria”. Journal of Nutrition 128 (2): 220–223. PMID 9446847. 
  11. ↑ Ronden, JE; Drittij-Reijnders M-J, Vermeer C, Thijssen HHW (1998). „Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat”. Biochimica et Biophysica Acta (BBA) - General Subjects 1379 (1): 69–75. DOI:10.1016/S0304-4165(97)00089-5. PMID 9468334. 

Vidi još[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]

Portal Medicina
Portal Hemija
  • „Glakay” (PDF). Eisai Co.. November 2009. Arhivirano iz originala na datum 2012-01-21. Pristupljeno 10. 1. 2012. 
Izvor: https://sh.wikipedia.org/w/index.php?title=Menatetrenon&oldid=41488706